Trying to get Fortis back on track, not going anywhere: Singh brothers

Fortis is being compared to Satyam, which the company vehemently denies

Malvinder Mohan Singh, Shivinder Mohan Singh
Fortis Healthcare executive chairman Malvinder Mohan Singh and non-executive chairman Shivinder Mohan Singh (right)
Veena Mani New Delhi
Last Updated : Feb 23 2018 | 1:13 AM IST
Fortis Healthcare founders Malvinder Mohan Singh and Shivinder Mohan Singh have said they are not shying from their responsibilities and even though they have resigned from the posts of executive chairman and non-executive vice-chairman, respectively, they are trying to get Fortis Healthcare back on track.

Their statement comes at a time when analysts tracking the hospital chain say that the brothers are losing hold. 

“Matters as large and complex as the ones being faced cannot be simplistically addressed and solutions require time,” their statement said. 

Fortis is being compared to Satyam, which the company vehemently denies. Reports suggest that the Singh brothers diverted company funds for their own interests. 

It had been reported that the auditors of the company did not sign the company’s second-quarter results, as the Singh brothers did not declare where those funds were utilised. The results for the quarters ended September and December have not yet been declared by the company. The board has decided to declare the results on February 28. 

Leading stock exchange the NSE said on Thursday derivative trading in Fortis Healthcare would be stopped if the company failed to submit its financial results for last two quarters by March 1. The Securities Exchange Board of India is investigating the matter. Fortis is also under the scanner of the Serious Fraud Investigation Office.

Lenders invoking their pledged shares have reduced the Singh brothers’ shares to 5.87 per cent from 34.43 per cent. On February 2, the Delhi High Court had ordered the Singhs to pay ~35 billion to Japanese drugmaker Daiichi Sankyo. The amount was 35 per cent of the ~100 billion the Singhs had received for selling their stake in Ranbaxy — then valued at $4.6 billion — to Daiichi in 2008.

There have been operational problems as well in the recent past. One of the major controversies had been the death of a minor in their Gurugram hospital. The hospital was blamed for medical negligence and overcharging. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story